Verastem, Inc. (VSTM) Form 424B5 — Oct 14, 2026
Verastem priced a $250 million underwritten offering of 30,937,500 shares at $8.00 per share, a premium to the $7.45 prior close, plus pre-funded warrants on 312,503 shares at $7.9999. Estimated net proceeds are approximately $234.7 million after $15.0 million in underwriting discounts. Proceeds will fund continued clinical development of VS-7375, a selective oral KRAS G12D inhibitor, plus working capital. Jefferies, Guggenheim, and Cantor are book-runners with B.
Key figures
- Gross Proceeds
- 249999992.75
- Offering Price
- 8
- Shares Offered
- 30937500
- Shares Outstanding
- 121419115
- Lockup days
- 60
- Net proceeds estimate
- 234700000
- Prior close oct13 2026
- 7.45
- Pre funded warrant price
- 7.9999
- As adjusted ntbv per share
- 2.21
- Offering expenses estimate
- 300000
- Pre funded warrants shares
- 312503
- Underwriting discount total
- 15000001.44
- Immediate dilution per share
- 5.79
- Shares outstanding pre offering
- 90481615
- Historical ntbv per share jun30 2026
- 0.38
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.